• Oncology
  • Current

IOmx Therapeutics is a novel immuno-oncology target discovery and drug development company.  It’s founders have developed a high-throughput siRNA-based screening approach that allows a comprehensive identification of ligands on human cancer cells that inhibit CTL-mediated tumor cell killing. To date, this screening technology has been applied to tumor cells derived from breast cancer, pancreatic cancer,melanoma and multiple myeloma. More than twenty novel targets have been identified which form the basis of the company’s pre-clinical product portfolio.